Mer­ck­'s Keytru­da wins an­oth­er first — this time for an FDA nod to treat a sub­set of blad­der can­cer pa­tients

Keytru­da, the star im­muno-on­col­o­gy ther­a­py des­tined to be­come the world’s best­selling drug by 2024, has se­cured ap­proval for a sub­set of blad­der can­cer pa­tients that so far have not had ac­cess to check­point in­hibitor treat­ment.

On Wednes­day, its mak­er Mer­ck said the block­buster an­ti-PD-1 med­i­cine had been sanc­tioned by the FDA for use in cer­tain pa­tients with high-risk, non-mus­cle in­va­sive blad­der can­cer (NMIBC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER